Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey

This article was originally published in The Pink Sheet Daily

Executive Summary

The Swiss drug company has set a goal of generating 60% of sales in emerging markets by 2015.

You may also be interested in...

Nycomed Expands In Turkey, Despite Tough Pharma Environment

Swiss pharmaceutical manufacturer Nycomed has acquired rights from specialty pharmaceutical company Biomeks Ilac (Biomeks) to market a portfolio of over ten pharmaceutical products in Turkey

Russia Pledges $3.9 Billion For Local Pharma Growth, As Big Pharma Scrambles To Set Up Shop

Russia has called for half of all pharmaceuticals in the country to be produced domestically in the next decade, pledging to spend 122.9 billion rubles ($3.97 billion) to get international drug makers to shift drug production to the country and strengthen R&D collaboration

Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma

Following through on a goal to expand operations in one of the world's fastest growing markets, Nycomed AS confirmed Nov. 1 that it is beefing up its Chinese presence through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts